Unmet medical need

Currently only a few adjuvants are accepted by regulatory authorities. Better adjuvants are needed to increase the efficacy of existing and newly developed vaccines, to reduce the dose of antigen or to overcome the need of multiple vaccinations. Many experimental adjuvants have been shown to enhance immune responses in small rodent species but their performance in larger species and humans is mostly disappointing. So, there is a need for better products but also for more predictive screening models.